LakeShore Biopharma Co., Ltd (LSB)

Market Cap	31.73M
Revenue (ttm)	84.75M
Net Income (ttm)	-13.78M
Shares Out	41.21M
EPS (ttm)	-0.72
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	87,494
Open	0.8100
Previous Close	0.8100
Day's Range	0.7556 - 0.8400
52-Week Range	0.4100 - 6.8200
Beta	0.57
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 19, 2025

About LSB

LakeShore Biopharma Co., Ltd, a biopharmaceutical company, discovers, develops, manufactures, commercializes, and sells vaccines and therapeutic biologics for infectious diseases and cancer. Its product pipeline includes YSJA, a conventional rabies vaccine, which is in marketed stage; PIKA, a rabies vaccine, which is in phase I/III and preclinical trials for the treatment of rabies virus; PIKA YS-ON-001, an immuno-oncology therapeutic candidate that is in phase I trial for the treatment of pancreatic and hepatocellular cancer; PIKA YS-HBV-001, ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Employees: 573
• Stock Exchange: NASDAQ
• Ticker Symbol: LSB
• Website: https://www.lakeshorebio.com

Financial Performance

In 2024, LakeShore Biopharma's revenue was 614.96 million, an increase of 7.24% compared to the previous year's 573.42 million. Losses were -99.98 million, -76.93% less than in 2023.

Financial numbers in CNY